The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Recent research out of Cornell University showed that GLP-1 users' grocery bills have been reduced by as much as 8.6% — with ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Josh Gad says he's taking 'life-changing' GLP-1 medication for weight loss but admits that it can't replace having a healthy ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...